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3INSERM, U773, Hoˆpital Beaujon, Clichy 92118, FrancePrimary Budd-Chiari syndrome is characterized by a blocked hepatic venous outﬂow tract at various levels from small
hepatic veins to inferior vena cava, resulting from thrombosis or its ﬁbrous sequellae. This rare disease aﬀects mainly
young adults. Multiple risk factors have been identiﬁed and are often combined in the same patient. Myeloproliferative
diseases of atypical presentation account for nearly 50% of patients; their diagnosis can be made by showing the
V617F mutation in Janus tyrosine kinase-2 gene of peripheral blood granulocytes and, should this mutation be absent,
by showing clusters of dystrophic megacaryocytes at bone marrow biopsy. Presentation and manifestations are extremely
varied, so that the diagnosis must be considered in any patient with acute or chronic liver disease. Doppler-ultrasound,
computed tomography or magnetic resonance imaging of hepatic veins and inferior vena cava are usually successful in dem-
onstrating non-invasively the obstacle or its consequences, the collaterals to hepatic veins or inferior vena cava. The disease
is considered to be spontaneously lethal within 3 years of ﬁrst symptoms. A therapeutic strategy has been proposed where
anticoagulation, correction of risk factors, diuretics and prophylaxis for portal hypertension are used ﬁrst; then angio-
plasty for short-length venous stenoses; then TIPS; and ultimately liver transplantation. Treatment progression is dictated
by the response to previous therapy. This strategy has achieved 5-year survival rates approaching 90%. Medium-term
prognosis depends on the severity of liver disease. Long-term outcome might be jeopardized by transformation of under-
lying conditions and hepatocellular carcinoma.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Budd-Chiari syndrome is characterized by an obstruc-
tion of the hepatic venous outﬂow tract in the absence of
right heart failure or constrictive pericarditis [1]. By con-
vention, hepatic veno-occlusive disease (recently renamed
sinusoidal obstruction syndrome) occurring in the setting
of an exposure to toxic plants or therapeutic agents is also
excluded. The obstacle causingBCS can thus be located at
the level of the small or large hepatic veins, or on the0168-8278/$34.00  2008 European Association for the Study of the Liver.
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the blockage is caused by invasion or compression by a
tumour, BCS is considered secondary, an entitywhichwill
not be discussed here. Otherwise, it is related to thrombo-
sis and considered primary.
Recent years have witnessed signiﬁcant advances in
several areas. The purpose of this article is to provide
an update oriented towards the practical management
of this disease.2. Epidemiology
Primary BCS is a rare disease. In the late 1980s, in
Japan and in France, incidence estimates derived from
questionnaire surveys were about 0.2 per million inhab-Published by Elsevier B.V. All rights reserved.
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2 per million inhabitants [2,3]. However, in Nepal, the
disease appeared to be at least 10 times more common,
and represented the leading cause for hospital admission
in a liver unit [4,3]. Current estimates are lacking. There
were diﬀerences between Asian and Western individuals
with BCS: terminal IVC was frequently obstructed in
Asians, and usually patent in Western patients. How-
ever, this pattern has changed over time in India, where
obstruction of terminal IVC now accounts for a lesser
proportion of cases [5,6]. Most aﬀected Western patients
have been young females whereas in Asia, middle-aged
patients of either sex were predominantly aﬀected.
Recent data from a European cohort however indicate
a change in demographics as the male to female ratio
is closer to 1 and mean age is about 45 years [7].Table 1
Approximate prevalence of major risk factors in patients with primary
BCS
Prevalence (%)3. Pathogenesis of venous lesions
At the time of presentation, venous involvement may
take the aspect of a fresh thrombus, superimposed on a
previous stenosis, or of a mere stenosis. The latter may
involve the entire length of a hepatic vein or of IVC;
or be localized to a short portion of it, even taking the
aspect of a membrane or ‘web’. In all instances, the pri-
mary lesion is a thrombus, later evolving toward a
ﬁbrous sequellae [8]. Short length stenoses are particu-
larly visible in the cephalad segment of inferior vena
cava or major hepatic veins [9].
Rarely, venous involvement occurs simultaneously in
all hepatic veins. Usually, there is an asynchronous and
progressive involvement which progresses at a variable
speed. The obstruction is followed by the development
of a collateral circulation by-passing the obstacle by
connecting blocked territories to contiguous territories
that have remained well-drained. The collaterals can
run an intra- or extra-hepatic course.Inherited conditions
Antithrombin deﬁciency 5
Protein C deﬁciencya 20
Protein S deﬁciencya 7
Heterozygous Factor V Leiden 20
Heterozygous G20210A prothrombin 7
Acquired conditions
V617F JAK2 positive MPD 40
V617F JAK2 negative MPD 10
Antiphospholipid syndrome 10
Behcet’s disease 5
PNH 2
Other general condition 5
External factors
Oral contraceptives in women 50
Multiple factors including local factors 35
No factor 5
Data are averages from reports reviewed elsewhere [54] and from more
recent reports [12,17,20,55,56].
a May be over-diagnosed due to liver dysfunction.4. Etiology
This is an important aspect of Budd-Chiari syn-
drome, a disease best understood as the hepatic expres-
sion of underlying prothrombotic conditions,
particularly blood diseases. As improved outcome of
BCS as a liver disease has resulted from advances in
management, the importance of underlying conditions
for therapy and long-term outcome has been revealed.
4.1. Multifactorial etiology
Recent data from several centres have consistently
shown that primary BCS must be regarded as a multi-
factorial disease where several prothrombotic disorders
must concur for the development of thrombosis at thisuncommon location. A combination of several pro-
thrombotic conditions has been observed in at least
35% of patients, which is several times higher than
expected in the general population [10–12]. It is of note,
however, that a local (non-tumorous) factor is seldom
identiﬁed, which contrasts with thrombosis in other
venous territories. This multifactorial paradigm explains
ﬁrst the rarity of the disease by the uncommon concur-
rence of factors which, individually, might not be very
uncommon. Second, the diﬀering features among vari-
ous areas or populations mentioned above can be
explained by diﬀerent combinations of various causes,
depending on their background prevalence in the spe-
ciﬁc area or population (e.g. oral contraceptives in the
West, extreme poverty in Asia and South Africa, as out-
lined below). The impact of this multifactorial paradigm
for clinical practice is that identiﬁcation of one causal
factor should not halt the search for other factors. Table
1 summarizes the prevalence of the major causal factors
reported in patients with primary BCS. Table 2 presents
a summary of the diagnostic work-up for etiology of
Budd-Chiari syndrome. Individual risk factors are dis-
cussed below.
4.2. Myeloproliferative diseases (MPDs)
MPDs account for about 50% of BCS patients, an
enormous proportion compared to the background
prevalence which might be in the order of 0.2% [13]. A
recent, crucial, advance in the ﬁeld of chronic MPD
has been the identiﬁcation of a particular somatic muta-
tion (V617F) in the Janus tyrosine kinase-2 (JAK2) gene
Table 2
Proposed work-up for investing underlying risk factors of Budd-Chiari
syndrome
A. In all patients
- Personal and familial history of recurrent spontaneous deep
vein thrombosis
- Oral contraceptive use in female patients
- V617F JAK 2 mutation in peripheral blood granulocytes.
When the mutation is undetected, bone marrow biopsy looking
for clusters of dystrophic megacaryocytes
(myeloproliferative diseases)
- Flow cytometry for CD55 and CD59 deﬁcient blood cells
(paroxysmal nocturnal hemoglobinuria)
- Activated protein C resistance. When present molecular test
for Factor V Leiden mutation
- Molecular test for G20210A prothrombin gene mutation
- Lupus anticoagulant, anti beta2 glycoprotein-1 antibodies,
anticardiolipin antibodies (antiphospholpid syndrome)
B. In patients with no marked liver dysfunction (normal prothrombin
level)-
Protein C, protein S and antithrombin plasma levels
- Plasma homocystein levels
C- In patients with familial or personal history of recurrent
spontaneous deep vein thrombosis: refer to blood coagulation
specialist for a detailed study
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tor receptor on the cells of the myeloid lineage. Activa-
tion by the ligand (erythropoietin, thrombopoietin or
other growth factors) elicits the signal for proliferation
and diﬀerentiation of the myeloid precursors into
mature cells through JAK2 phosphorylation. V617F
JAK2 mutation produces constitutive activation of sig-
nal transduction resulting in independence from, or
hypersensitivity to, growth factors. This single somatic
mutation can be detected in granulocytes or other blood
cells of the myeloid lineage. V617F JAK2 has been
found in about 80% and 50% of patients with polycythe-
mia vera, and essential thrombocythemia or idiopathic
myeloﬁbrosis, respectively [15]. In patients with primary
BCS, the mutation has been detected in 37–45% of
patients [12,16–20]. Other somatic mutations of the
JAK2 gene or other genes have been identiﬁed in
MPD, but they appear to account for only a minor pro-
portion of the cases [17]. Also clusters of dystrophic
megacaryocytes at bone marrow biopsy proved recently
to be a speciﬁc feature for MPD [21]. About 80% of BCS
patients with a MPD harbour V617F JAK2 mutation
[12,17]. In the remaining patients, evidence for the
underlying MPD is derived from bone marrow biopsy
ﬁndings. Testing for JAK2 mutation and bone marrow
biopsy have replaced formerly used tests using cultures
of erythroid progenitors to demonstrate endogenous
colonies.
Peripheral blood cell counts remain within normal
values in most patients with MPD when BCS is present,
due to hypersplenism, hemodilution and iron deﬁciency.
In the past, this lack of typical changes in peripheralblood has represented a major limitation to the recogni-
tion of MPD. In practical terms, this means that all BCS
patients, whatever the results of their blood cell counts,
should be tested for V617F JAK2 in peripheral granulo-
cytes, followed by bone marrow biopsy in those patients
that test negative for the mutation. At present, uncer-
tainties remain as to which of these patients with an
essentially normal blood cell count should receive cyto-
reductive therapies. Advances are expected from the
possibility to quantify the mutated cells.
4.3. Other acquired conditions
Behcet’s disease usually causes BCS through its well-
known involvement of the IVC. However, cases of pure
hepatic vein involvement have also been reported
[22,23]. In areas where Behcet’s disease is prevalent, it
represents the leading cause for BCS.
Paroxysmal nocturnal hemoglobinuria is an extre-
mely rare disease with a frequently devastating course.
The cumulative incidence of hepatic vein thrombosis is
extraordinarily high in this disease (about 35%). Fea-
tures of blood disease are varied so that tests for parox-
ysmal nocturnal hemoglobinuria should be obtained
routinely in all BCS patients. Flow-cytometry on
peripheral blood for detection of the CD55 and CD59
deﬁcient clone is the current standard for diagnosis.
Recently, a speciﬁc treatment with eculizumab has been
shown to reduce the incidence of haemolytic as well as
thrombotic episodes [24,25]. Bone marrow transplanta-
tion has been successfully performed in some patients
with BCS.
The prevalence of antiphospholipid syndrome cannot
be clearly ascertained as anticardiolipin antibodies are
commonly found in patients with a chronic liver disease,
whatever its origin [26]. Using stringent criteria, the
prevalence of antiphospholipid syndrome has been esti-
mated to be about 15% among BCS patients. Finding
lupus anticoagulant is stronger evidence for anti-
phospholipid syndrome than anti beta2 glycoprotein-1
antibodies. Anticardiolipin antibodies appear to be the
least speciﬁc features unless they are repeatedly detected
at high titers. There is no speciﬁc therapy yet available
for this condition.
As plasma homocysteine levels are increased in
patients with liver disease [27], the role of hyperhom-
ocysteinemia as a cause for BCS is similarly diﬃcult
to evaluate. However, the assessment of vitamin deﬁ-
ciencies is certainly worth while in patients with
thrombosis.
Oral contraceptive use has long been known as a risk
factor for BCS, particularly the form with pure hepatic
vein involvement. Pregnancy also appears to be a trig-
gering factor for hepatic vein thrombosis. However, in
both instances, an underlying condition is usually pres-
ent [11,28].
198 D.-C. Valla / Journal of Hepatology 50 (2009) 195–203Last, pure IVC obstruction has been associated to a
very poor standard of living in a case control study,
although the mechanism by which this occurs has not
been clariﬁed yet [4]. This association conveniently
explains the predominance of IVC obstruction among
BCS patients from some areas of the world [6,29].
4.4. Inherited conditions
Identiﬁcation of Factor V Leiden as a risk factor for
venous thrombosis has been another major advance for
the understanding of BCS pathogenesis. Factor V Lei-
den accounts for 7–25% of patients with primary BCS,
a proportion similar to that found in patients with deep
venous thrombosis of the lower limbs [5,10,11,30]. In
most BCS patients, factor V Leiden is associated with
other risk factors for thrombosis, as expected from its
relatively weak thrombotic potential [30].
By contrast, G20210A prothrombin gene mutation,
another recently discovered inherited prothrombotic
disorder, appears to be less over-represented among
BCS patients than the former prothrombotic conditions
[10–12].
The prevalence of primary deﬁciencies in protein C,
protein S or antithrombin among BCS patients is
diﬃcult to estimate for the following reasons: (a) these
coagulation inhibitors are synthesized by the liver; (b)
the diagnosis of primary deﬁciencies is based on the
determination of the plasma level (most mutations are
private which makes a diagnosis by molecular biology
alone diﬃcult); (c) liver dysfunction related to BCS
induces a non-speciﬁc decrease in plasma levels of these
inhibitors; and (d) complete family screening is usually
impossible. In most cases, the issue of a possible primary
deﬁciency will thus remain unanswered [31].
A number of systemic diseases have been incrimi-
nated (sarcoidosis, cryptogenic bowel disease, hypereo-
sinophilic syndrome, etc.). Collectively, these diseases
account for only a minority of the cases.
Other recently identiﬁed inherited risk factors [32]
have not been extensively studied in BCS patients. In
any case, it is obvious that not all inherited risk factors
for thrombosis have been identiﬁed yet [33].
In practical terms, in a patient with decreased coagu-
lation factor levels or marked liver dysfunction, and
without a family history of idiopathic thrombosis, it
would seem futile to test for diagnostic purpose, plas-
minogen, protein C, protein S, or antithrombin deﬁ-
ciency, serum homocysteine and plasma factor VIII
levels.
4.5. Site-speciﬁcity for thrombosis
The increasing amount of available data lends sup-
port to the concept of site-speciﬁcity for thrombosis
according to the underlying prothrombotic disorder[10,16,19]. MPD is clearly more common among
BCS patients than among patients with portal vein
thrombosis, and even more so than among patients
with venous thrombosis at other sites. Factor V Lei-
den is more strongly associated with BCS than with
portal vein thrombosis, whereas the converse appears
to apply to G20210A prothrombin. Further site-spec-
iﬁcity might be present also within the hepatic venous
outﬂow tract itself. Indeed, factor V Leiden appears to
be particularly common in patients with IVC obstruc-
tion [30]. Furthermore, oral contraceptives and preg-
nancy have been speciﬁcally associated with hepatic
vein involvement [3].
Although these considerations are of little practical
signiﬁcance at present, in the future they may help in
the understanding of an important observation: the
usual lack of a local – mechanical or inﬂammatory –
factor explaining why thrombosis develops at such an
unusual site in the context of a general prothrombotic
condition [10].5. Clinical and laboratory features
Various forms of presentation and course have been
described, ranging from fulminant to chronic, the latter
being the most frequent one. Asymptomatic forms
appear to account for about 15% of patients [34]. These
asymptomatic forms are characteristically associated
preservation of some hepatic veins and IVC, or with
large intrahepatic or extrahepatic collaterals.
The clinical manifestations of BCS have been well
characterized [6,34,35]. Abdominal pain, ascites, liver
and spleen enlargement, and portal hypertension are
important features, as well as a prominent dilation of
subcutaneous veins of the trunk in those patients with
long standing IVC obstruction. Each or all of these fea-
tures may, however, be lacking. Liver function tests are
altered to a various extent according to patients.
Presentation bears little relationship with the actual
duration of the disease. Most patients presenting with
acute manifestations have extensive ﬁbrosis or cirrhosis.
Less than 10% of patients presenting with an acute ill-
ness actually have a recent disease [6,36].
In BCS patients, HCC appears to be as signiﬁcant as
a long-term complication as it is in other chronic liver
diseases. HCC developed in 11 of 97 patients of a recent
cohort followed-up for a mean of 5 years [37]. Serum a
foetoprotein appeared to be more speciﬁc for a diagno-
sis of HCC in patients with BCS than with other liver
diseases. Patients with long-standing IVC obstruction
carried a risk of developing HCC that was 70-fold
higher than those with pure hepatic vein involvement.
Multivariate analyses in larger cohorts, as well as molec-
ular studies are further needed to clarify HCC patho-
physiology in this non-inﬂammatory disease of the liver.
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The marked clinical and pathological heterogeneity
among BCS patients partly stems from the diversity of
location of the obstruction (IVC or major hepatic veins),
but also from the variable number of obstructed hepatic
veins [38], and likely from the various speed of the
obstructive process. In addition, a deleterious role of a
loss of intrahepatic portal perfusion has been demon-
strated in patients undergoing liver transplantation [39].
In these patients with end-stage liver disease, there was
a close relationship between deprivation of portal blood
supply, and liver cell loss in the corresponding areas. Por-
tal venous deprivation can result either from intrahepatic
portal vein thrombosis, or from focally retrograde portal
blood ﬂow. Thus, maintenance of portal blood supply
might be crucial for preventing progression of liver dis-
ease. Regenerative macronodules, occasionally mimick-
ing focal nodular hyperplasia, are found in arterialized
liver, in those areas that are deprived of portal perfusion
but apparently well-drained by hepatic venous collaterals
[39]. Nodular regenerative hyperplasia is commonplace in
these arterialised livers [39].
Extrahepatic portal vein thrombosis is superimposed
on BCS in about 15% of patients [40]. As compared with
patients having a patent portal vein, manifestations at
diagnosis were not more severe and, although survival
tended to be decreased, the diﬀerence was not statisti-
cally signiﬁcant [40]. Therefore, it might be that super-
imposed extrahepatic portal vein thrombosis is mainly
a consequence of portal vein blood stasis, in a context
of multiple prothrombotic factors. According to this
view, superimposed extrahepatic portal vein thrombosis
might be a reﬂection of severe liver disease rather than a
factor for its aggravation.
The asynchronous involvement of the hepatic veins,
and the mechanisms of atrophy-hypertrophy which
result, explain that a markedly dysmorphic liver is com-
mon. The hypertrophy of the central parts of the liver
(mainly the caudate lobe) is related in part to the main-
tenance of an adequate venous drainage through the
numerous small caudate lobe veins that reach the IVC
directly; and for another part, to a better preservation
of portal perfusion than in the peripheral areas.
BCS-related hepatic ﬁbrosis diﬀers from that related
to alcoholic or viral liver disease, by its predominant,
although not exclusive, centrilobular distribution. In
addition, the RNA expression of ﬁbrogenic and angio-
genic factors diﬀers from that of chronic liver disease
related to alcohol or viral hepatitis [41].7. Diagnosis
A diagnosis of BCS should be considered in any
patient with acute or chronic liver disease. Obviously,the diagnosis is more likely when there is no other, more
common, cause of liver disease; or when there is a
known underlying prothrombotic condition.
Diagnosis is based on the demonstration of an
obstructed hepatic venous outﬂow tract [42]. For that
purpose, modern, non-invasive imaging means are most
eﬃcient, provided two conditions are fulﬁlled. The
examiner should (a) be experienced and (b), be aware
of the clinical diagnostic suspicion. The arguments for
an obstruction comprise a dilatation of the vein
upstream to an obstacle; the presence of a solid endolu-
minal material; the transformation of the veins into a
cord devoid of ﬂow signal; and venous collaterals, seen
as abnormal circulating structures branching to or from
the hepatic veins or IVC. Doppler-ultrasound, triphasic
CT scan or MRI is usually suﬃcient to show these diag-
nostic features. Patchy enhancement of hepatic paren-
chyma is only suggestive of a perfusion defect, which
can be seen in many other vascular disorders of the liver.
At present, there is almost no place for direct or retro-
grade venography, for the sole purpose of making a
diagnosis of BCS [1].
Liver biopsy is of diagnostic interest only in the rare
forms of the disease where thrombosis is limited to the
small intrahepatic veins, i.e. with a normal appearance
of the large veins at non-invasive imaging [1]. Biospy
usually brings non-speciﬁc evidence for an impaired
blood outﬂow, including congestion, coagulative necro-
sis or simple loss of hepatocytes without inﬂammatory
inﬁltrates, and/or ﬁbrosis, all features predominating
in the centrilobular area. Such features of outﬂow
obstruction are encountered in patients with BCS,
veno-occlusive disease, or cardiac or pericardial disease.
Thrombosis of the hepatic veins is an uncommon ﬁnd-
ing in needle biopsy specimens. In clinical practice, the
most challenging diﬀerential diagnosis is constrictive
pericarditis.8. Natural course and prognosis
Fortuitously recognized, asymptomatic forms carry a
good prognosis [34]. Symptomatic forms have a poor
spontaneous course as it has been estimated that 90%
of untreated patients will die within 3 years [43]. Death
can be related to refractory ascites leading to emacia-
tion, hepatic failure, gastrointestinal bleeding, or a com-
bination thereof.
Contrasting with a high degree of heterogeneity in
causes, presentation, and level of hepatic venous outﬂow
block, it is remarkable that all the prognostic information
appears to be accounted for by the components of the
Child-Pugh score or the MELD score [7]. However, it
should be kept inmind that thesemarkers are poor predic-
tors of the outcome in an individual patient. Therefore,
they are of no help in the practical management. The
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for clinical studies adjusting the outcome of patient
groups on their baseline characteristics.9. Treatment
Randomized clinical trials of treatment options are
still lacking. International expert panel conferences have
permitted a consensual elaboration of recommendations
based on comprehensive reviews of evidence, and on the
confrontation of experience in referral centres [1,44].
Recent studies have generally supported these
recommendations.
9.1. Underlying disease
Logically, prompt recognition and treatment of
underlying diseases has been recommended. However,
data on these aspects are largely lacking. Speciﬁc ther-
apy for the underlying causes, if any, should be applied
early. This important aspect is beyond the scope of this
article. There is hope that recent advances in the under-
standing of MPD and newly available agents for parox-
ysmal nocturnal haemoglobinuria will result in a clinical
beneﬁt for BCS patients aﬀected with these diseases. For
many conditions, particularly antiphospholipid syn-
drome and hereditary thrombophilias, anticoagulation
therapy remains the only available therapeutic means.
Recombinant antithrombin is available for deﬁcient
patients but only for use over a limited period of time
[45].
9.2. Anticoagualtion therapy
Early initiation of anticoagulation therapy is recom-
mended for all patients regardless of whether an under-
lying prothrombotic disorder has been identiﬁed or not
[1,44]. Although anticoagulation has not been evaluated
in randomized clinical trials, there is much circumstan-
tial evidence for a favourable beneﬁt/risk ratio in BCS
patients [1]. Immediate anticoagulation is therefore rec-
ommended [44]. This treatment will be suﬃcient in con-
trolling the liver disease in 10% of patients, mainly those
with a mild disease [45]. A surprisingly high incidence of
heparin induced thrombocytopenia has been reported
with unfractionated heparin [45] and, more recently,
with low-molecular weight heparins [46]. These ﬁndings
have remained unexplained. However, it is safe to rec-
ommend that unfractionated heparin,be avoided as it
can be replaced by low molecular weight heparin for ini-
tiation of anticoagulation. There is no evidence that the
eﬃcacy of vitamin K antagonists diﬀers from that of
heparin. At present, therefore, the choice for the type
of anticoagulation should be dictated by pharmacoki-
netic considerations and by context, i.e. a need for rapidand short acting anticoagulation therapy, or long-term
treatment.
9.3. Percutaneous angioplasty
About a third of patients harbour short length steno-
sis either of the hepatic veins or of the IVC. Such
patients are candidates for percutaneous transluminal
angioplasty. The eﬃcacy and the inocuity of this proce-
dure (with or without stenting) have been conﬁrmed, at
least when a retrograde, transjugular or transfemoral
route is used [45,47]. Therefore, active search for such
short-length stenoses, and when found, an appropriate
percutaneous intervention, have been recommended in
patients with symptomatic BCS. In asymptomatic
patients, the beneﬁt-risk ratio of this therapeutic option
is still debated. Available data suggest signiﬁcant proce-
dure-related morbidity with the transhepatic approach
to hepatic vein angioplasty, which is considered when
a transvenous approach has failed.
Taken together, anticoagulation and angioplasty
appear to succeed in controlling BCS in only 20–30%
of patients, at least in a Western series where pure hepa-
tic vein involvement predominates [45].
9.4. Transjugular intrahepatic portosystemic shunt
Consistent data indicate that in patients where the
disease is not fully controlled by the preceding options,
the next step should be TIPS insertion. Indeed, in expe-
rienced hands, the transcaval approach is technically
and clinically successful in most patients [47–49]. Fur-
thermore, the advent of covered stents has allowed
maintained patency for prolonged periods [48].
Increased diﬃculties and morbidity of the procedure in
BCS patients as compared with the usual cirrhotic
patients should not be underestimated. Improved sur-
vival in TIPS treated patients is most obvious among
those with the most severe disease at baseline. In that
subset of patients, 5-year survival rose from 45% in a
reference cohort – where TIPS was only marginally used
– [50], to 71% in a series of TIPS treated patients [51].
Overall, 60% of current Western patients may require,
and be satisfactorily treated with, a covered-stent TIPS.
9.5. Liver transplantation
In the remaining 10–20% of patients, anticoagulation,
percutaneous angioplasty and TIPS fail either due to
technical failure or to poor clinical results of a techni-
cally successful procedure. In such patients, liver trans-
plantation is the remaining option. Two recent
retrospective analyses of the outcome in large series of
transplanted patients have shown 5-year survival rates
reaching 80% [52,53]. The true impact of liver transplan-
tation is diﬃcult to assess based on these two studies, as
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similar severity given less demanding treatments. Most
recent reports suggest that previous attempt at TIPS
or percutaneous stenting of the outﬂow tract did not
compromise the results of liver transplantation [53].
Patients with blocked portal vein are poor candidates
to TIPS or liver transplantation, although each of these
procedures has been reported to be successful in a few
patients [40]. Therefore, maintenance of a patent portal
vein clearly stands as a major therapeutic target. How-
ever, it should be remembered that after adjustment
for severity at diagnosis of BCS, prognosis was not inﬂu-
enced by the presence of portal vein obstruction [40,50].
This means that compensated patients with preservedTable 3
Proposed treatment strategy for Budd-Chiari syndrome
A. In all patients
- Initiate anticoagulation immediately
 Use low molecular weight heparin (in the absence of known
allergy)
 Monitor platelet counts every other day. Sustitute heparin
for daparanoid sulphate when there is a drop in platelet counts.
Perform tests for heparin-induced thrombocytopenia to
establish or rule out diagnosis
 Monitor antifactor X activity (heparinemia). Check
antithrombin level if a target level of 0.5 IU/ML cannot be
achieved using conventional doses. Administer recombinant
antithrombin if level below 50% of normal
 Shift to oral anticoagulation targeting an INR 2 to 3 as
soon as possible
- Refer to the haematologist for paroxysmal nocturnal
hemoglobinuria and myeloproliferative disease. Consider rapid
cytoreductive therapy in patients with myeloproliferative disease
and increased blood cell counts. Stop oral contraceptives and
hormonal therapy Provide prophylactic therapy for portal
hypertension and treat active bleeding according to guidelines
for cirrhosis
- Treat ascites with diuretics and blood volume expansion if
needed. Limit to minimum the number of paracentesis because
of the risk of intraperitoneal bleeding on anticoagulation
- Monitor clinical improvement (encephalopathy, weight, fever,
pain), decrease in serum transaminase level, decrease in serum
bilirubin and creatinine if previously abnormal, increase in
prothrombin level (or, on anticoagulation, factor V level) and
response and tolerance to diuretics
- Consider risk, beneﬁt and possible technical diﬃculties of
angioplasty in patients with short length stenosis in hepatic
vein or inferior vena cava
B. In patients not improving or deteriorating with the above measures,
proceed to angioplasty with or without stenting, if appropriate.
Indication can be broad when the risk of the procedure is deemed
minimal
C. Proceed to insertion of a covered TIPS when the patient is not
responding to the above treatments whether angioplasty has been
technically successful or not. Revise TIPS as needed based on
clinical, Doppler-ultrasound and hemodynamic assessment
D. Consider liver transplantation when the patient is not responding
to the above treatments unless TIPS dysfunction can be correctedliver function despite extensive blockade of the splanch-
nic veins usually have prolonged survival when treated
only with anticoagulation, and percutaneous angio-
plasty of the outﬂow tract when possible.
The implementation of these treatment procedures
requires experienced operators. Furthermore, patients
should be managed in close cooperation with a trans-
plantation center, as an emergency transplantation
may happen to be indicated. Indications for percutane-
ous manoeuvres are based on imaging and haemody-
namic data obtained at IVC and hepatic vein
catheterization. Thus, while venograpy has little place
among diagnostic procedures, it occupies a central place
in the elaboration of therapy.
The above strategy is summarized in Table 3. This
strategy aiming at minimal invasiveness is based on
response to previous therapy rather than on the actual
severity of the patient. It has allowed to achieve 5-year
survival rates in the order of 90% [7,45,47]. This consid-
erable improvement in survival expectancy has been
obtained together with an excellent quality of life due
to complete resolution of clinical signs and symptoms,
and quasi-normalization of liver function tests [45].
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